Illumina Earnings Preview: Can This Streak Continue?

Illumina (NASDAQ:ILMN) will report earnings after markets close on Tuesday, July 23rd. Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies.

Here is your Cheat Sheet to Illumina Earnings:

Earnings Expectations: Analysts expect earnings of $0.39 per share on revenues of $331.71 million. Currently, the company’s P/E ratio stands at 94.97.

Analyst Trends:

Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a profit of $0.4 to a profit $0.39. For the current year, the average estimate is a profit of $1.67, which is better than the estimate ninety days ago.

Earnings Trends:

Here’s how Illumina has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 573 666 903 1,056 1,149
Diluted EPS ($) 0.38 0.53 0.87 0.62 1.13

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012 Mar. 31, 2013
Revenue ($) in millions 280.61 285.87 309.27 330.96
Diluted EPS ($) 0.18 0.22 0.53 -0.18

Past Performance:
Illumina has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]